Table 2 (Abstract A18).
PRO scores of the BECOME study population set for Part 2 by PPTF and MMD
| PRO questionnaires | Part 2 (N=2419) | |||
|---|---|---|---|---|
| 1 PPTF (n=1034) | 2 PPTF(n=690) | 3 PPTF (n=324) | ≥4 PPTF (n=371) | |
| EQ-5D-5L utility index score | 0.78 (0.22) | 0.76 (0.22) | 0.72 (0.24) | 0.72 (0.22) |
| EQ VAS score | 70.3 (19.85) | 66.8 (20.07) | 64.5 (20.31) | 62.0 (20.94) |
| HIT-6 total score | 64.6 (5.74) | 65.1 (5.69) | 66.4 (5.03) | 66.3 (5.14) |
| MIDAS disability grade IV, n (%) | 802 (77.6) | 565 (81.9) | 283 (87.3) | 332 (89.5) |
| 4–7 MMD(n=806) | 8–14 MMD(n=605) | ≥15 headache days/month, of which ≥8 are migraine days (n=1007) | ||
| EQ-5D-5L utility index score | 0.82 (0.19) | 0.81 (0.19) | 0.68 (0.24) | |
| EQ VAS score | 73.7 (17.88) | 72.6 (17.74) | 59.0 (20.71) | |
| HIT-6 total score | 63.6 (5.89) | 65.0 (5.41) | 66.7 (5.04) | |
| MIDAS disability grade IV, n (%) | 583 (72.3) | 492 (81.3) | 907 (90.1) | |
All values are mean (SD) unless otherwise indicated. EQ-5D-5L, EuroQol 5 dimensions 5 levels; HIT, Headache Impact Test; MIDAS, migraine disability assessment; MMD, monthly migraine days; N, total number of patients; n, number of patients; PPTF, prior prophylactic treatment failures; PRO, patient-reported outcomes; VAS, visual analogue scale